Selmod is performing the research and clinical development of new anti-infective therapies to the end-of-phase 2 approval.

The number of 700’000 AMR deaths p.a. worldwide is increasing constantly and estimated to reach up to 10 million AMR deaths p.a. worldwide by 2050.
The post-antibiotic era has become reality. The changing reimbursement options generate opportunities for our start-up. Selmod aims for business opportunity in a re-emerging market.

Selmod is a Swiss biotech start-up.

Selmod was founded in May 2016 in Basel, Switzerland.
Selmod is supported by Venturelab, VentureKick, Innosuisse and by private investors.